K. Reed

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

R. D'Andrea, A. Wei, A. Dear, 2014, Blood Cancer Journal.

Pilot study of an outpatient‐based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim

C. Arthur, A. Spencer, K. Reed, 2007, Internal medicine journal.

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

A. Wei, O. Gervásio, S. Avery, 2011 .

A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma

Edmond J. Breen, A. Spencer, K. Reed, 2019, Blood Cancer Journal.

A multicenter phase 2 study of risk‐adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma

J. Catalano, A. Grigg, C. Arthur, 2008, Cancer.

A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients.

G. Nichol, L. Cohen, A. Spencer, 2010 .